Prelude Therapeutics Inc Stock Price, News & Analysis

Prelude Therapeutics (Nasdaq: PRLD) announced new preclinical data presentations at the 2025 AACR Annual Meeting for two key programs. The first presentation focuses on PRT3789, their first-in-class selective SMARCA2 degrader currently in Phase 1 and 2 clinical trials for advanced solid tumors with SMARCA4 loss.

The second presentation highlights their KAT6A degrader program, showing promising preclinical results in breast cancer and other solid tumors. Their selective KAT6A degraders demonstrated:

• Deep anti-cancer responses in KAT6A-amplified tumors
• Complete tumor regressions in breast and lung cancer xenografts
• Reduced hematologic toxicity compared to KAT6A/B inhibitors
• Effectiveness against endocrine therapy and CDK4/6i-resistant cells

Prelude Therapeutics (Nasdaq: PRLD) reported its full year 2024 financial results and clinical program updates. The company's lead drug PRT3789, a first-in-class SMARCA2 degrader, demonstrated clinical proof-of-concept with anti-tumor activity in SMARCA4-deficient cancers. Of 32 evaluable patients, 5 showed confirmed partial responses.

Financial highlights include:

• Cash position of $133.6 million as of December 31, 2024, funding operations into Q2 2026
• R&D expenses increased to $118.0 million from $103.4 million in 2023
• Net loss of $127.2 million ($1.68 per share) compared to $121.8 million ($2.02 per share) in 2023

Key upcoming milestones include additional results from PRT3789 monotherapy and docetaxel combination studies, plus interim data from oral SMARCA2 degrader PRT7732 in H2 2025. The company also plans to seek a partner for its CDK9 inhibitor PRT2527 to focus on SMARCA2 degrader development.

Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, FL on March 11, 2025.

Key executives participating in a fireside chat at 12:30 p.m. ET include:

• Kris Vaddi, Ph.D., Chief Executive Officer
• Jane Huang, M.D., President and Chief Medical Officer
• Bryant Lim, Chief Financial Officer

The event will be accessible via live webcast on the Company's website under Events and Presentations, with the recording remaining available for 90 days. Prelude Therapeutics specializes in developing innovative medicines for cancer patients, focusing on:

• First-in-class SMARCA2 degraders (IV and oral)
• CDK9 inhibitor development
• Precision ADCs (Degrader Antibody Conjugates) through partnerships

Prelude Therapeutics (NASDAQ: PRLD) presented interim clinical data from its Phase 1 dose-escalation trial of PRT2527, a CDK9 inhibitor, both as monotherapy and combined with zanubrutinib in relapsed/refractory lymphoid malignancies. The study included 46 patients across multiple dosing cohorts.

Key findings showed an overall response rate of 17.4% (4 of 23 patients) for monotherapy and 38.5% (5 of 13 patients) for combination therapy. The drug demonstrated an acceptable safety profile, with neutropenia (48%) and nausea (33%) as the most common side effects. The company has selected the 18 mg/m2 dose level for confirmation and plans to seek a partner for future development while focusing resources on their SMARCA degrader programs.

Prelude Therapeutics (Nasdaq: PRLD) has announced its participation in the upcoming Citizens JMP Securities Hematology and Oncology Summit, scheduled for December 2, 2024. The virtual event will feature a fireside chat at 11:30 a.m. ET with CEO Kris Vaddi, Ph.D., and President/CMO Jane Huang, M.D. The session will be available via webcast on the company's website and archived for 90 days.

Prelude Therapeutics specializes in precision oncology, developing innovative medicines for high-unmet cancer patient needs. Their pipeline includes first-in-class SMARCA2 degraders (both IV and oral) and a CDK9 inhibitor. The company is also advancing Precision ADCs through partnerships.

Prelude Therapeutics (PRLD) reported Q3 2024 financial results and clinical updates. Key highlights include interim data from Phase 1 study of PRT3789, showing clinical proof of concept in SMARCA4-mutated cancers. The company initiated Phase 1 trial for PRT7732 and presented preclinical data from its Precision ADC platform. Financial position remains strong with $153.6M cash runway into 2026. Q3 net loss was $32.3M ($0.43/share). R&D expenses increased to $29.5M from $26.3M year-over-year, while G&A expenses rose to $7.9M from $7.1M.

Prelude Therapeutics presented interim data from its ongoing Phase 1 trial of PRT3789, a SMARCA2 degrader for cancer patients with SMARCA4 mutations. Of 65 patients treated, the drug showed promising results with 4 confirmed partial responses among 26 evaluable NSCLC or esophageal patients with Class 1 mutations. Higher doses demonstrated deeper SMARCA2 degradation, with 2 of 9 NSCLC patients showing confirmed responses at doses of 283mg or higher.

The drug was generally well-tolerated, with mostly mild to moderate adverse events. Initial combination study with docetaxel showed an acceptable safety profile. The company also presented first preclinical proof-of-concept data from their novel SMARCA2/4 dual degrader payload program.

Prelude Therapeutics (Nasdaq: PRLD) announced the publication of three abstracts for presentation at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain from October 23-25, 2024. The abstracts focus on the company's SMARCA Degrader Programs, including:

1. First clinical results from a Phase 1 trial of PRT3789, a first-in-class SMARCA2 degrader, in patients with advanced solid tumors with SMARCA4 mutations.

2. Discovery of first-in-class precision antibody drug conjugates with a potent SMARCA 2/4 dual degrader payload.

3. The selective SMARCA2 degrader, PRT3789, enhancing the efficacy of standard chemotherapy in SMARCA4 mutant NSCLC models.

Prelude expects to conclude monotherapy dose escalation for PRT3789 by year-end 2024 and identify the biologically active dose for future trials. The company is also enrolling patients in back-fill cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations at higher dose levels.

Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activity in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:

- 3 confirmed partial responses observed
- 7 out of 26 evaluable NSCLC or esophageal patients showed tumor shrinkage
- Generally well-tolerated safety profile with no dose-limiting toxicities
- Dose escalation continuing to 9th cohort (500mg once weekly)

The company plans to confirm the biologically active dose for PRT3789 monotherapy by year-end and advance combination studies with docetaxel. These results represent initial proof of concept for selective SMARCA2 degradation in certain SMARCA4 mutated cancers.